HIGHLIGHTS FROM OUR LAST SHOW

The health AI economy is growing rapidly. The sector is projected to generate over US$187 billion in global revenue by 2030, according to industry analysts (Grand View Research), and will support hundreds of thousands of roles spanning clinical informatics, software engineering, governance, and regulatory affairs. There is significant potential for validated, evidence-based health AI. Healthcare systems are already deploying first-generation diagnostic and decision-support tools, many of which were built and evaluated under conditions that no longer reflect the complexity of real-world clinical environments. The first rigorously validated health AI systems are beginning to emerge from research partnerships and regulatory pilots. By the end of this decade, the expectation is that only those systems with demonstrated clinical safety and robust post-market surveillance will retain deployment approval. New applications are being added continuously, including AI-assisted pathology, clinical decision support for emergency triage, predictive models in aged care, AI-driven radiology interpretation, and intelligent patient flow management across hospital networks.

Australian health technology companies are investing in clinical validation frameworks and are positioned to benefit from their deep expertise in healthcare delivery and digital health integration. A validated health AI system generates actionable, reproducible clinical outputs and supports measurable improvements in patient outcomes. Developers speak of deployment-scale models operating across entire health networks, being systems capable of supporting the diagnostic and administrative workload of a major regional health service or a network of primary care practices. Depending on clinical requirements and patient volume, these systems can be configured and scaled to support population-level health management. Other regions across the Asia-Pacific are simultaneously supplying and consuming health AI technology. An international perspective is essential: Australia is not self-sufficient in health AI development, and cross-border collaboration on standards, training data, and validation methodology will shape the sector's trajectory.

Clinical Validation Requires Robust Evidence

Real-world clinical evidence has an important role to play here. Prospective clinical trials, post-deployment monitoring, and independent external evaluation will all become standard requirements as the regulatory framework matures. With health AI, the challenge is more complex than traditional medical device evaluation. Tools that change after deployment, whether through model updates, retraining, or environmental drift, unsettle traditional evaluation methods. Continuous validation approaches will be needed for safe, sustained deployment. According to clinical informatics experts, meaningful validation requires evidence generated across diverse patient populations, clinical settings, and care contexts. Many existing systems could meet evolving standards, but only after rigorous post-market assessment; upgrading the evidentiary base is crucial. That is why health services with strong data infrastructure and clinical research capacity are coming into focus as preferred validation partners.